Trandolapril/verapamil combination in hypertensive diabetic patients

Vascular Health and Risk Management

Volumn 3, Issue 1, 2007, Pages 77-82

  García Donaire, Jose A ^a   Ruilope, Luis M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Combination therapy; Diabetes; Hypertension; Renin angiotensin system; Trandolapril; Verapamil

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL PLUS CHLORTALIDONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; LONG ACTING DRUG; PLACEBO; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL; VERAPAMIL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; HEART FAILURE; HOMEOSTASIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; METABOLIC REGULATION; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; REVIEW; STROKE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; INDOLES; TREATMENT OUTCOME; VERAPAMIL;

EID: 34249850530     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Adler AI, Stratton IM, Neil HA, et al. 2000. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ, 321:412-19.
2. Bakris GL, Weir MR, DeQuattro V, et al. 1998. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int, 54:1283-9.
3. Bakris GL, Williams M, Dworkin L, et al.; for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. 2000. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis, 36:646-61.
4. Bakris GL, Gaxiola E, Messerli FH, et al. 2004. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension, 44:637-42.
5. Brenner BM, Cooper ME, de Zeeuw D, et al. 200 1. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 345:861-9.
6. Cifkova R, Nakov R, Novozamska E, et al. 2000. Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. J Hum Hypertens, 14:347-54.
7. Curb JD, Pressel SL, Cutler JA, et al. 1996. Effect of diuretic-based anti-hypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA, 276:1886-92.
8. [ESH-ESC] European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. 2003. J Hypertens, 21:1011-53.
9. Fernandez R, Puig JG, Rodriguez-Perez JC, et al.; TRAVEND Study Group. 200 1. Effect of two antihypertensive combinations on metabolic control in type 2 diabetic hypertensive patients with albuminuria: a randomized, double-blind study. J Hum Hypertens, 15:849-56.
10. Hanefeld M, Fischer S, Julius U, et al. 1996. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabetologia, 39:1577-83.
11. Hansson L, Zanchetti A, Carruthers SG, et al. 1998. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 351:1755-62.
12. Hilleman DE, Ryschon KL, Mohiuddin SM, et al. 1999. Fixed-dose combinations versus monotherapy in hypertension: a meta-analysis evaluation. J Hum Hypertens, 13:477-83.
13. [HOPE] Heart Outcomes Prevention Evaluation Study Investigators. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med, 342:145-53.
14. [HOPE] Heart Outcomes Prevention Evaluation (HOPE) Study investigators. 2000a. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet, 355:253-9.
15. [HDS] Hypertension in Diabetes Study Group (HDS). 1993. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardio-vascular and diabetic complications. J Hypertens, 11:309-17.
16. Jarrett JR, Fitzgerald AP. 1994. Non-insulin-dependent diabetes mellitus, glucose intolerance, blood pressure, hypertension and antihypertensive drugs. Diabet Med, 11:646-9.
17. [JNC] The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. 2003. JAMA, 289:2560-72.
18. Kannel W, McGee D. 1979. Diabetes and cardiovascular disease. The Framingham Study. JAMA, 241:2035-8.
19. Klein R. 1995. Hyperglycaemia and microvascular and microvascular disease in diabetes. Diabetes Care, 18:258-68.
20. Knuiman MW, Welborn TA, McCann VJ, et al. 1986. Prevalence of diabetic complications in relation to risk factors. Diabetes, 35:1332-9.
21. Lehto S, Ronnemaa T, Haffner SM, et al. 1997. Dyslipidemia and hyperglycaemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes, 46:1354-9.
22. Lewis EJ, Hunsicker LG, Clarke WR, et al. 2001. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 345:851-60.
23. MacMahon S, Peto R, Cutler J, et al. 1990. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged difference in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet, 335:765-74
24. Muijsers BR, Curran M, Perry C. 2002. Fixed combination trandolapril/ verapamil sustained release. Drugs, 62:2539-67
25. Oliveira SA, Lapuerta P, McCarthy BD, et al. 2002. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med, 162:413-20.
26. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. 2001. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med, 345:870-8.
27. Pepine C, Handberg E, Cooper-De Hoff et al.; for the INVEST investigators. 2003. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA, 290:2805-16.
28. PROCOPA study group. 2002. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial. J Hypertens, 20:729-37
29. Ravid M, Savin H, Jutrin I, et al. 1993. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and in on proteinuria in normotensive type 2 diabetic patients. Ann Intern Med, 118:577-81
30. Ruggenenti P, Fassi A, Ilieva AP, et al.; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) investigators. 2004. Preventing microalbuminuria in type 2 diabetes. N Engl J Med, 351:1941-51.
31. Ruilope LM, de la Sierra A, Moreno E, et al. 1999. Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. J Hypertens, 17:1917-23.
32. Ruilope LM, Salvetti A, Jamerson K, et al. 2001. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol, 12:218-25.
33. Ruilope LM, Usan L, Segura J, et al. 2004. Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en Diabéticos tipo Dos) study. J Hypertens, 22:217-22.
34. Schrier RW, Estacio RO, Esler A. 2002. Effects of aggressive blood pressure control on normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int, 651:1086-97.
35. Sowers JP, Sowers PS, Peuler JD. 1994. Role of insulin resistance and hiperinsulinemia in development of hypertension and atherosclerosis. J Lab Clin Med, 123:647-52.
36. Teuscher A, Weidmann P. 1997. Requirements for antihypertensive therapy in diabetic patients: metabolic aspects. J Hypertens, 15(Suppl 2):S67-S75.
37. Tuomilehto J, Rastenyte, D, Birkenhäger WH, et al. 1999. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med, 340:677-84.
38. Vasan RS, Larson MG, Leip EP, et al. 2001. Impact of high-normal blood pressure on the risk of cardiovascular disease. Framingham Heart Study. N Engl J Med, 345:1291-12.
39. Zanchetti A, Ruilope, LM. 2002. Antihypertensive treatment in patients with type 2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens, 20:2099-110.